scholarly journals La sindrome da iperstimolazione ovarica: tra clinica ed etica

2006 ◽  
Vol 55 (2) ◽  
Author(s):  
Zoya Serebrovska ◽  
Maria Luisa Di Pietro

La sindrome da iperstimolazione ovarica è la complicanza più seria dell’induzione dell’ovulazione, a cui si ricorre in presenza di insufficienza dell’asse ipotalamo-ipofisi-ovaio o nei protocolli di fecondazione artificiale. Si tratta di una malattia tipicamente iatrogena, che comprende una serie di disfunzioni e varia da una forma benigna ad una condizione estremamente grave fino alla morte della donna. A fronte della difficoltà di interpretare i meccanismi eziopatogenetici responsabili e di attuare una reale prevenzione, sono stati proposti diversi accorgimenti. D’altra parte, in quanto malattia iatrogena, la sindrome da iperstimolazione ovarica pone in modo forte l’interrogativo sulla doverosità di tale prevenzione, anche se appare necessaria una riflessione molto più ampia proprio sulle giustificazioni e sui limiti della cosiddetta “medicina della riproduzione”. ---------- Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of the induction of ovulation during the treatment of hypothalamus-hypophysis- ovary insufficiency or under the protocols of artificial fertilization. OHSS is a tipically iatrogenic disease, which contains different dysfunctions and varies from very soft forms to extremely grave conditions and even to death of woman. The mechanisms of the aetiology and pathogenesis of OHSS is still very unclear and there are serious problems of prevention. Because of iatrogenic origin of the syndrome, the question of necessity of prevention becomes even more urgent, and occupies an important place in the very large discussion about the justifications and the limits of so called “medicine of reproduction”.

GYNECOLOGY ◽  
2017 ◽  
Vol 19 (6) ◽  
pp. 19-23
Author(s):  
G E Chernukha ◽  
E K Kaprina ◽  
A A Naidukova

The aim of the study was to evaluate the effectiveness of the use of letrozole as an inducer of ovulation in women with polycystic ovary syndrome (PCOS) and anovulatory infertility and to determine possible clinical and laboratory predictors of the effect of therapy. Materials and methods: 61 women with anovulatory infertility and PCOS (mean age 28.5 ± 3.3 years, mean body mass index - BMI 21.8 ± 2.7 kg / m2) were included in the study. In order to induce ovulation, the patient received letrozole at a dose of 2.5-5 mg / day from day 3 to 7 of the menstrual cycle under the control of folliculometry, ultrasound m / pelvis on the 20-24 day cycle and the level of progesterone in the blood. Results: the frequency of ovulation per cycle was 77.2% (146/189), 98.4% for women, 24.9% for conception (47/189), 77% for women (47/61) , in 6 (12.8%) women the pregnancy was biochemical, in 1 (2.1%) ectopic, multiple pregnancy took place in 2 (5%) women with progressive uterine pregnancy, spontaneous abortion in the period up to 12 weeks of gestation occurred in 5 (12.5%) women, there was no case of ovarian hyperstimulation syndrome or other side effects. Comparative analysis revealed higher levels of BMI, the percentage of total adipose tissue by densitometry, and the number of antral follicles in the volume of the ovaries in the group with no pregnancy. Conclusion: letrozole is an effective medication for induction of ovulation and pregnancy in the treatment of infertility in patients with PCOS, characterized by good tolerability, low risk of multiple pregnancies and the absence of cases of ovarian hyperstimulation syndrome.


1996 ◽  
Vol 76 (02) ◽  
pp. 275-277 ◽  
Author(s):  
Sylvie Hollemaert ◽  
Jean-Claude Wautrecht ◽  
Paul Capel ◽  
Marc J Abramowicz ◽  
Yvon Englert ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document